SCHEMBL19769010

SCHEMBL19769010

CC(C)c1cccc(F)c1-c1ncc[nH]1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.48
ADRA2A P08913 2/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
NISCH Q9Y2I1 2/20 0.40
MTOR P42345 1/20 0.40
ADK P55263 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
F2RL1 P55085 10/20 0.39
PTGER3 P43115 1/20 0.36
MC4R P32245 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821845 0.89 TAAR1 (0.54) TAAR1ADRA2AADRA2BADRA2CNISCH
Hydrochloric Acid SCHEMBL28055288 0.87 TAAR1 (0.53) TAAR1ADRA2AADRA2BADRA2CNISCH
Bromide SCHEMBL31606836 0.87 TAAR1 (0.53) TAAR1ADRA2AADRA2BADRA2CNISCH
SCHEMBL23492894 0.85 ADRA2A (0.38) TAAR1ADRA2AADRA2BADRA2CNISCH
SCHEMBL28021702 0.84 TAAR1 (0.50) TAAR1ADRA2AADRA2BADRA2CNISCH
SCHEMBL28766423 0.84 TAAR1 (0.50) TAAR1ADRA2AADRA2BADRA2CNISCH
SCHEMBL6002691 0.83 NISCH (0.50) TAAR1ADRA2AADRA2CNISCHMTOR
SCHEMBL19782078 0.79 NISCH (0.44) TAAR1ADRA2ANISCHMTORADK
SCHEMBL28829249 0.76 NISCH (0.43) ADRA2ANISCHMTORADKMEN1
SCHEMBL22096835 0.75 TAAR1 (0.49) TAAR1NISCHMTORADKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-06-10 US disclosed
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed
US-10351547-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2019-07-16 US disclosed
US-20190002431-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2019-01-03 US disclosed
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 US disclosed
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 US disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 TAAR1 415/4885ADRA2A 259/4885ADRA2B 223/4885
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 TAAR1 415/4885ADRA2A 259/4885ADRA2B 223/4885
US-10351547-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 TAAR1 415/4885ADRA2A 259/4885ADRA2B 223/4885
US-20190002431-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 TAAR1 415/4885ADRA2A 259/4885ADRA2B 223/4885
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 TAAR1 415/4885ADRA2A 259/4885ADRA2B 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.